



Centre For AIDS Reagents

Data Sheet

NAME:	Tenofovir disoproxil fumarate
REPOSITORY REFERENCE:	ARP986
DESCRIPTION:	Tenofovir disoproxil fumarate is a prodrug of Tenofovir. Cellular ezymes convert tenofovir disoproxil fumarate to tenofovir diphosphate. Tenofovir diphosphate inhibits the activity of HIV reverse transcriptase by competing with the natural substrate, deoxyadenosine 5'-triphosphate, which after incorporation causes chain termination. Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases.
PRESENTATION:	20 mg
LOT NUMBER:	7 098127
SOLUBILITY:	Soluble in water at 13.4mg/mL; Also soluble in methanol and moderately soluble in ethyl acetate and methylene chloride. Insoluble in hexanes.
CHEMICAL NAME:	2, 4, 6, 8-Tetraoxa-5-phosphanonanedioic acid 5-[[(1R) -2-(6- amino-9Hpurin-9-yl)-1-methylethoxy]-methyl]-bis (1 methylethyl) ester 5-oxide (2E)-2-butenedioate (1:1)
MOLECULAR WEIGHT:	635.52
STORAGE:	Room temperature. Once resuspended, working aliquots can be stored at - 20°C.
SOURCE:	Division of AIDS, NIAID.
ACKNOWLEDGEMENT:	Publications should acknowledge the donor of the reagent and the Programme EVA Centre for AIDS Reagents. Suggested wording can be found on our website at <u>http://www.nibsc.ac.uk/spotlight/aidsreagent/index.html</u> in the "Acknowledgements" section. Please also ensure that you send us a copy of any papers resulting from work using reagents acquired through CFAR (this can be Electronically or as a paper copy)

National Institute for Biological Standards and Control – Assuring the quality of biological medicines Blanche Lane South Mimms Potters Bar Hertfordshire EN6 3QG United Kingdom Tel +44 (0)1707 641000 Fax +44 (0)1707 641050 www.nibsc.ac.uk A World Health Organization Laboratory for Biological Standards







NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the AIDS Research and Reference Reagent Program, NIAID, NIH: Tenofovir disoproxil fumarate."

This compound is restricted for "research purposes only" and is limited to 40 mg per requester per year. Not available for release to commercial organizations outside of the USA. Recipient agrees that the reagent (Tenofovir disoproxil fumarate) use is permitted only as a standard f or in vitro and/or studies in animals for inhibition of HIV replication.

